In total, 63.6% (7 out of 11) of tumours with an amplification of HER2 presented a deletion (6 homozygous) of PTEN (83.3% of the SDCs) in comparison with only 20% (37 out of 185) PTEN deletions in the non-amplified carcinomas (P<0.001). The gene discussed is PTEN; the disease is neoplasm.